Expression status of p53 and organic cation transporter 1 is correlated with poor response to preoperative chemotherapy in esophageal squamous cell carcinoma.
Cisplatin
Esophageal squamous cell carcinoma
Organic cation transporter 1
Preoperative chemotherapy
p53
Journal
World journal of surgical oncology
ISSN: 1477-7819
Titre abrégé: World J Surg Oncol
Pays: England
ID NLM: 101170544
Informations de publication
Date de publication:
01 Apr 2022
01 Apr 2022
Historique:
received:
25
08
2021
accepted:
21
03
2022
entrez:
2
4
2022
pubmed:
3
4
2022
medline:
6
4
2022
Statut:
epublish
Résumé
Esophageal squamous cell carcinoma (ESCC) is a highly malignant neoplasm. DNA-damaging drugs, such as cisplatin (CDDP) and 5-fluorouracil (5-FU), are most frequently used in preoperative chemotherapy for ESCC. However, the response to preoperative chemotherapy varies among patients. p53, encoded by TP53, participates in apoptotic pathways following chemotherapy with DNA-damaging drugs, and mutation of TP53 contributes to chemoresistance. Organic cation transporter 1 (OCT1) participates in the uptake of CDDP, and its reduced expression is associated with CDDP resistance. The aim of this study was to evaluate the predictive impact of the expression status of p53 and OCT1 in response to preoperative chemotherapy in ESCC. We retrospectively assessed 66 ESCC patients who received preoperative chemotherapy with CDDP/5-FU (CF) or docetaxel/CDDP/5-FU (DCF). p53 and OCT1 expression in pretreatment biopsy specimens was immunohistochemically determined and correlated with histological response to preoperative chemotherapy. p53 with wild-type (p53 Our results suggest that either p53
Sections du résumé
BACKGROUND
BACKGROUND
Esophageal squamous cell carcinoma (ESCC) is a highly malignant neoplasm. DNA-damaging drugs, such as cisplatin (CDDP) and 5-fluorouracil (5-FU), are most frequently used in preoperative chemotherapy for ESCC. However, the response to preoperative chemotherapy varies among patients. p53, encoded by TP53, participates in apoptotic pathways following chemotherapy with DNA-damaging drugs, and mutation of TP53 contributes to chemoresistance. Organic cation transporter 1 (OCT1) participates in the uptake of CDDP, and its reduced expression is associated with CDDP resistance. The aim of this study was to evaluate the predictive impact of the expression status of p53 and OCT1 in response to preoperative chemotherapy in ESCC.
METHODS
METHODS
We retrospectively assessed 66 ESCC patients who received preoperative chemotherapy with CDDP/5-FU (CF) or docetaxel/CDDP/5-FU (DCF). p53 and OCT1 expression in pretreatment biopsy specimens was immunohistochemically determined and correlated with histological response to preoperative chemotherapy.
RESULTS
RESULTS
p53 with wild-type (p53
CONCLUSIONS
CONCLUSIONS
Our results suggest that either p53
Identifiants
pubmed: 35365176
doi: 10.1186/s12957-022-02571-9
pii: 10.1186/s12957-022-02571-9
pmc: PMC8976339
doi:
Substances chimiques
Organic Cation Transporter 1
0
Tumor Suppressor Protein p53
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
105Subventions
Organisme : Japan Society for the Promotion of Science
ID : 20K07391
Informations de copyright
© 2022. The Author(s).
Références
Ann Surg Oncol. 2010 Feb;17(2):634-42
pubmed: 19941080
Proc Natl Acad Sci U S A. 1990 Dec;87(24):9958-61
pubmed: 2263646
Cancer Res. 2006 Sep 1;66(17):8847-57
pubmed: 16951202
Esophagus. 2017;14(1):37-65
pubmed: 28111536
Dis Esophagus. 2000;13(3):191-7
pubmed: 11206631
J Surg Oncol. 2011 Aug 1;104(2):169-75
pubmed: 21462189
Dis Esophagus. 2002;15(1):61-6
pubmed: 12060045
Clin Cancer Res. 2016 Sep 1;22(17):4283-90
pubmed: 27370606
Cell Death Differ. 2003 Apr;10(4):431-42
pubmed: 12719720
J Pathol. 1994 Jan;172(1):1-4
pubmed: 7931821
Pathol Res Pract. 2019 Jul;215(7):152425
pubmed: 31097354
J Pathol. 1995 Jan;175(1):7-12
pubmed: 7891229
Lancet. 2002 May 18;359(9319):1727-33
pubmed: 12049861
Cancers (Basel). 2020 Aug 12;12(8):
pubmed: 32806706
Br J Cancer. 1994 Jan;69(1):26-31
pubmed: 7506924
Mol Cell Ther. 2014 May 27;2:15
pubmed: 26056583
Anticancer Res. 2000 May-Jun;20(3B):1933-7
pubmed: 10928129
Dig Dis Sci. 2013 Mar;58(3):694-8
pubmed: 23053895
Eur J Cancer. 2000 May;36(8):987-93
pubmed: 10885602
Esophagus. 2019 Jan;16(1):1-24
pubmed: 30171413
Drug Resist Updat. 2012 Feb-Apr;15(1-2):5-20
pubmed: 22459901
Mod Pathol. 2011 Sep;24(9):1248-53
pubmed: 21552211
Science. 1994 Nov 4;266(5186):807-10
pubmed: 7973635
Eur J Cancer. 1997 Jul;33(8):1221-5
pubmed: 9301446
J Pharmacol Exp Ther. 2006 Nov;319(2):879-86
pubmed: 16914559
Cancer. 1997 Feb 1;79(3):425-32
pubmed: 9028350
Gen Thorac Cardiovasc Surg. 2016 Apr;64(4):209-15
pubmed: 26868531
J Natl Cancer Inst. 1996 Oct 16;88(20):1442-55
pubmed: 8841019
Curr Drug Metab. 2011 Oct;12(8):793-807
pubmed: 21787263
Nat Rev Cancer. 2001 Dec;1(3):233-40
pubmed: 11902578
Ann Surg Oncol. 2012 Mar;19(3):757-65
pubmed: 21947696
J Pathol. 1992 Apr;166(4):329-30
pubmed: 1517889
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Ann Surg Oncol. 2012 Jan;19(1):68-74
pubmed: 21879261
J Thorac Cardiovasc Surg. 2014 Nov;148(5):2280-6
pubmed: 25135238